Is more chemo better?

Is more chemo better?

The group that got the continuous but gradually lower dose of chemo showed the best response in terms of slowing tumor growth. In up to 80% of the animals, their tumors continued to shrink to the point where they eventually didn’t need any additional chemotherapy at all.

What kind of chemo is oxaliplatin?

Oxaliplatin is a type of chemotherapy drug. It is also called Eloxatin. It’s a treatment for bowel cancer and some other types of cancer. You usually have oxaliplatin in combination with other chemotherapy drugs.

What is rechallenge chemotherapy?

Chemotherapy rechallenge was defined as the re-use of a drug that had been administered earlier in the course of treatment and stopped due to disease progression or toxicity. At least one line of treatment had to have been received between first use and re-use.

Which is better CAPOX or folfox?

Patients who received CAPOX were significantly older than those who received FOLFOX. Disease progression, metastasis, and mortality rates were significantly higher in the FOLFOX arm than in the CAPOX arm. There was no significant difference in the overall survival rate between the two regimens.

How bad is oxaliplatin?

Oxaliplatin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.

What is the most aggressive chemotherapy?

Doxorubicin (Adriamycin) is one of the most powerful chemotherapy drugs ever invented. It can kill cancer cells at every point in their life cycle, and it’s used to treat a wide variety of cancers.

How toxic is oxaliplatin?

In the MOSAIC trial, grade 3 peripheral sensory neuropathy was noted in 12.5% of patients receiving oxaliplatin during treatment. After 48 months of follow up, the rates of toxicity observed were 11.9% grade 1, 2.8% grade 2 and 0.7% grade 3, respectively [Andre et al. 2009].

What is rechallenge in oncology?

Drug rechallenge and continuation of treatment following progression on therapy is not new in oncology. Rechallenging a tumour that has relapsed when the patient is not receiving therapy has been described for decades.

Is regorafenib a chemotherapy?

Regorafenib is the generic name for the trade name chemotherapy drug Stivarga®. In some cases, health care professionals may use the trade name Stivarga® when referring to the generic drug name regorafenib. Drug type: Regorafenib is a targeted therapy.

How effective is CAPOX?

The 3-year OS rates were 91% and 81% for stages II and III, respectively. The 3-year DFS rate was 74% for stage II and 66% for stage III. By multivariate analysis, only cancer stage was predictive of overall survival. Conclusions: CAPOX is an effective treatment for stage II and III CC in the adjuvant setting.

Is CAPOX associated with improved disease-free survival in colon cancer?

Conclusion: CAPOX may be associated with improved disease-free survival despite greater toxicities and lower RDI. Reducing adjuvant chemotherapy duration to 3 months would prevent 26% of patients from ever experiencing a DLT.

Are FOLFOX and CAPOX used interchangeably in adjuvant treatment of colon cancer?

Background: CAPOX and FOLFOX are used interchangeably in the adjuvant treatment of colon cancer despite the lack of comparative phase III trials.We aimed to compare toxicities, relative dose intensity (RDI), disease free (DFS) and overall survival (OS) of these regimens in the real world.

What is CAPOX used to treat?

Each of the drugs in this combination is approved by the Food and Drug Administration (FDA) to treat cancer or conditions related to cancer. CAPOX is used to treat: Colorectal cancer that is advanced. This combination may also be used with other drugs or treatments or to treat other types of cancer.

Does adjuvant CAPOX improve efficacy Despite toxicity and lower RDI?

Conclusions: Our findings suggest that the use of adjuvant CAPOX is associated with an improved DFS despite greater toxicity and lower RDI. Patient selection, the higher starting dose of oxaliplatin in CAPOX, or the metronomic nature of capecitabine may be contributing to improved efficacy of CAPOX.

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top